



Published in final edited form as:

*Mol Aspects Med.* 2008 October ; 29(5): 290–308. doi:10.1016/j.mam.2008.05.002.

## Progress in matrix metalloproteinase research

Gillian Murphy<sup>a,\*</sup> and Hideaki Nagase<sup>b</sup>

<sup>a</sup> Department of Oncology, University of Cambridge, Cancer Research UK Cambridge Research Institute, Cambridge, UK

<sup>b</sup> Department of Matrix Biology, The Kennedy Institute of Rheumatology Division, Imperial College London, London W6 8LH, UK

### Abstract

Matrix metalloproteinases (MMPs) are now acknowledged as key players in the regulation of both cell–cell and cell–extracellular matrix interactions. They are involved in modifying matrix structure, growth factor availability and the function of cell surface signalling systems, with consequent effects on cellular differentiation, proliferation and apoptosis. They play central roles in morphogenesis, wound healing, tissue repair and remodelling in response to injury and in the progression of diseases such as arthritis, cancer and cardiovascular disease. Because of their wide spectrum of activities and expression sites, the elucidation of their potential as drug targets in disease or as important features of the repair process will be dependent upon careful analysis of their role in different cellular locations and at different disease stages. Novel approaches to the specific regulation of individual MMPs in different contexts are also being developed.

### Keywords

Matrixin; Tissue inhibitors of metalloproteinases; Cancer; Cardiovascular disease; Arthritis

## 1. Introduction

Normal physiological remodelling processes such as development, morphogenesis and tissue repair involve precisely regulated degradation of the extracellular matrix (ECM). Remodelling also occurs during the course of diseases such as arthritis, cancer and cardiovascular disease, in part in an attempt at repair, but is frequently dysregulated and destructive (Milner and Cawston, 2005; Newby, 2005; Sternlicht and Werb, 2001; Burrage and Brinckerhoff, 2007). Various types of proteinases have been implicated in ECM degradation, but a major enzyme group involved is that of the matrix metalloproteinases (MMPs), also called the matrixins. Most recent studies have shown that MMPs have other roles in the regulation of the cellular environment and modulating many bioactive molecules at the cell surface and can act in concert to influence cell behavior (Egeblad and Werb, 2002). In order to ascertain the potential of MMP inhibitors as therapeutics, one of the current major research challenges is to determine the specific function of individual enzymes in different cellular and temporal contexts in both normal and pathological processes.

## 2. The matrixin family members

In 1962 Gross and Lapiere first reported vertebrate collagenolytic activity in tadpole tissues (tailfin, skin, intestine and gill) undergoing metamorphosis (Gross and Lapiere, 1962). These

---

\*Corresponding author. Tel.: +44 1223 404470; fax: +44 1223 762323, gm290@cam.ac.uk (G. Murphy).

tissues are rapidly remodelling the ECM, hence triggering apoptosis, cell differentiation and growth (Shi et al., 1998). This discovery stimulated many researchers to look in human tissues, since degradation of collagen is important in wound healing, tissue regeneration and diseases such as arthritis, cancer, atherosclerosis, aneurysm and tissue ulcerations. The first human collagenase to be purified was from rheumatoid synovium (Woolley et al., 1975) which has similar properties to tadpole collagenase, cleaving triple helical type I collagen at a single site about 3/4 away from the N-terminus (Woolley et al., 1975). It took another 11 years to deduce the primary structure of human collagenase from fibroblasts (MMP-1) by cDNA cloning (Goldberg et al., 1986). This revealed a homology with a transcript reported in the previous year in rat fibroblasts induced by growth factor, oncogene and cellular transformation (Matrisian et al., 1985) which was later identified as rat MMP-3 (stromelysin 1). The human genome has 24 matrixin genes which include a duplicated *Mmp23* gene. Thus, there are 23 different MMPs. Matrixins are also found in fruit fly (*Drosophila melanogaster*), nematode (*Caenorhabditis elegans*), sea urchin (*Paracentrotus lividus*), hydra (*Hydra vulgaris*) and plants (*Arabidopsis thaliana*).

The matrixins are multidomain zinc metalloproteinases, but sequence homology with the catalytic domain of fibroblast collagenase (collagenase 1) or MMP-1 is a criterion for membership of the family. The MEROPS database (<http://www.merops.sanger.ac.uk>) classifies the MMPs/matrixin subfamily of metzincins as M10. The catalytic domain contains the Zn<sup>2+</sup> binding motif HEXXHXXGXXH and a conserved methionine, forming a 'Met-turn' eight residues downstream, which supports the active site cleft structure around the catalytic Zn<sup>2+</sup>. Thus, they are typical metzincin members (Bode et al., 1993), but what distinguishes MMPs from other metzincins are the primary structures of the catalytic domains. The matrixins are synthesized as pre-proenzymes and the signal peptide is removed during translation to generate proMMPs. The propeptides have the 'cysteine switch' motif PRCGXPD in which the cysteine residue coordinates with the catalytic Zn<sup>2+</sup> in the catalytic domain, keeping the proMMPs inactive (Van Wart and Birkedal-Hansen, 1990).

Table 1 lists the vertebrate MMPs. They are grouped into collagenases, gelatinases, stromelysins, matrilysins, membrane-type (MT)-MMPs and others and this grouping is based on domain organization and substrate preference, but is otherwise more or less historical; more recently discovered 'non-conformist' enzymes being grouped in the 'other' category. The use of bioinformatic methods to compare the primary sequences of the MMPs suggests six evolutionary sub-groups (A–F) of the MMPs: sub-group A, MMP-19, -26 and -28; sub-group B, MMPs -11, -21 and -23; sub-group C, MMP-17 and -25; sub-group D, MMP-1, -3, -8, -10, -12, -13 and -27; sub-group E, MMP-14, -15, -16 and -24; sub-group F, MMP-2, -7, -9 and -20 (Huxley-Jones et al., 2007).

### 3. Mammalian matrixins and their domain constituents

In this review we use the conventional grouping of the matrixins and only briefly discuss the main biochemical properties as many reviews have given detailed accounts of their substrate specificities (Overall, 2002; Nagase et al., 2006; Cauwe et al., 2007). Table 1 describes the domain composition of human matrixin members and their chromosome location, and Fig. 1 shows their domain composition and arrangements. Typically MMPs consist of a propeptide of about 80 amino acids, a catalytic metalloproteinase domain of about 170 amino acids, a linker peptide of variable lengths (also called the 'hinge region') and a hemopexin domain of about 200 amino acids. MMP-7 (matrilysin 1), MMP-26 (matrilysin 2) and MMP-23 are exceptions as they lack the linker peptide and the hemopexin domain. MMP-23 has a unique C-terminal cysteine-rich domain and an immunoglobulin-like domain immediately after the C-terminus of the catalytic domain.

### 3.1. Collagenases

There are three collagenases; collagenase 1 (MMP-1), collagenase 2, also called neutrophil collagenase (MMP-8) and collagenase 3 (MMP-13). They consist of propeptide, catalytic and hemopexin domains. They play an important role in cleaving fibrillar collagen types I, II and III into characteristic 3/4 and 1/4 fragments, but they also have activity against other ECM molecules and soluble proteins. The catalytic domains of collagenases can cleave non-collagenous substrates, but they are unable to cleave native fibrillar collagens in the absence of their hemopexin domains. The cooperation between the two domains is considered to be important for the expression of their collagenolytic activity (Chung et al., 2004).

### 3.2. Gelatinases

Gelatinase A (MMP-2) and gelatinase B (MMP-9) belong to this sub-group. Both enzymes have three repeats of a fibronectin type II motif inserted into the catalytic domain (Figs. 1 and 2). They share similar proteolytic activity and degrade denatured collagens, gelatins and a number of ECM molecules including native type IV, V and XI collagens, laminin and aggrecan core protein. MMP-2 digests native collagen types I, II and III in a similar manner to the collagenases (Aimes and Quigley, 1995; Patterson et al., 2001), but MMP-9 does not. However, the collagenolytic activity of MMP-2 is much weaker than MMP-1 or other collagenases in solution. Nevertheless, because proMMP-2 is recruited to the cell surface and activated by the membrane-bound MT-MMPs, it may accumulate pericellularly and express reasonable local collagenolytic activity. It may also act as a 'collaborator' activity, digesting collagenase-clipped collagen to smaller fragments because those fragments denature at body temperature 37 °C (Murphy et al., 1985).

### 3.3. Stromelysins

MMP-3, MMP-10 and MMP-11 are called stromelysins 1, 2 and 3, respectively. They have the same domain arrangement as the collagenases, but they do not cleave interstitial collagens. MMP-3 and MMP-10 are similar in structure and substrate specificity, but MMP-11 (stromelysin 3) is distantly related. MMP-3 and MMP-10 digest a number of ECM molecules and participate in proMMP activation, but MMP-11 has very weak activity toward ECM molecules (Murphy et al., 1993). Another difference is that both MMP-3 and MMP-10 are secreted from the cells as inactive proMMPs, but MMP-11 is activated intracellularly by furin and secreted from the cell as an active enzyme (Pei and Weiss, 1995). The MMP-11 gene is located on chromosome 22, whereas MMP-3 and MMP-10 are on chromosome 11, along with MMP-1, -7, -8, -12, -20, -26 and -27 (Table 1). An alternatively spliced transcript of MMP-11 lacking the signal peptide and the propeptide domain encode an active intracellular form, but its function is not known (Luo et al., 2002).

### 3.4. Matrilysins

MMP-7 and MMP-26 belong to this category. The structural feature of these MMPs is that they lack the hemopexin domain. MMP-7 is synthesized by epithelial cells and secreted apically. In the intestine it acts intracellularly to process procryptidins to bactericidal forms. It degrades ECM components, but it also cleaves cell surface molecules such as Fas-ligand, pro-tumor necrosis factor  $\alpha$ , syndecan 1 and E-cadherin to generate soluble forms, hence acting as a form of 'shedase' (Parks et al., 2004). MMP-26 is expressed in normal cells such as those of the endometrium and in some carcinomas and digests several ECM molecules (Marchenko et al., 2004).

### 3.5. Membrane-bound MMPs (MT-MMPs)

There are two types of MT-MMPs which include four type I transmembrane proteins (MMP-14, -15, -16 and -24) and two glycosylphosphatidylinositol-anchored proteins

(MMP-17 and -25). They all have a furin-like proprotein convertase recognition sequence RX [R/K]R at the C-terminus of the propeptide. They are therefore activated intracellularly and active enzymes are likely to be expressed on the cell surface. All MT-MMPs, except MT4-MMP (MMP-17) (English et al., 2001) can activate proMMP-2. MT1-MMP (MMP-14) can activate proMMP-13 on the cell surface (Knäuper et al., 1996). However, MT1-MMP itself has collagenolytic activity against type I, II and III collagens (Ohuchi et al., 1997). MT1-MMP null mice exhibit skeletal abnormalities during post-natal development, which is attributed to the lack of collagenolytic activity (Holmbeck et al., 1999).

### 3.6. Other MMPs

There are seven matrixins which are not catalogued in the above sub-groups. Among them MMP-12, MMP-20 and MMP-27 do have a similar domain arrangement and chromosome location as stromelysins. Therefore, it may be more appropriate to sub-group them into the stromelysins.

Metalloelastase (MMP-12) was originally discovered in macrophages, but is also found in hypertrophic chondrocytes (Kerkelä et al., 2001) and osteoclasts (Hou et al., 2004). It degrades elastin and a number of other ECM molecules and is essential in macrophage migration (Shiple et al., 1996b).

MMP-19 is a potent basement membrane-degrading enzyme, but it also digests other ECM molecules (Stracke et al., 2000). It is widely expressed in human tissues (Pendas et al., 1997) and is considered to play a role in tissue remodelling, wound healing and epithelial cell migration by cleaving the laminin 5  $\gamma$ 2 chain (Sadowski et al., 2003, 2005). MMP-19 deficient mice developed diet induced obesity and reduced skin cancer susceptibility (Pendas et al., 2004).

Enamelysin (MMP-20) is a tooth specific MMP expressed in newly formed tooth enamel and digests amelogenin (Ryu et al., 1999). MMP-20-null mice have a deteriorating enamel organ morphology due to the lack of amelogenin processing (Bartlett et al., 2004). Amelogenin imperfecta, a genetic disorder with defective enamel formation, is due to mutation at MMP-20 cleavage sites (Li et al., 2001).

MMP-21 is expressed in various fetal and adult tissues. It is also found in basal and squamous cell carcinomas (Ahokas et al., 2003) and macrophages of granulomatous skin lesions and in fibroblasts in dermatofibromas (Skoog et al., 2006). Information on its action on ECM components is not available, although it does have gelatinolytic activity.

MMP-23 is unique among the matrixin members as it lacks the cysteine switch motif in the propeptide and the hemopexin domain. The latter is substituted by cysteine-rich immunoglobulin-like domains (Velasco et al., 1999). It is a type II membrane protein having a transmembrane domain at the N-terminal of the propeptide, such that the enzyme is solubilized as the membrane anchored propeptide is cleaved by a proprotein convertase (Pei et al., 2000). It is expressed predominantly in ovary, testis and prostate, suggesting a specialized role in the reproductive process (Velasco et al., 1999).

MMP-27 was first cloned from chicken embryo fibroblast cDNA library (Yang and Kurkinen, 1998). The chicken enzyme digests gelatin and casein and causes autolysis of the enzyme, but little information is available on the activity of mammalian enzyme. MMP-27 is expressed in B-lymphocytes and its levels increase when treated with anti-(IgG/IgM) in culture (Bar-Or et al., 2003).

Epilysin (MMP-28) was first cloned from the human keratinocyte and testis cDNA libraries, and is expressed in many tissues such as lung, placenta, heart, gastrointestinal tract and testis (Lohi et al., 2001). The enzyme expressed in basal keratinocytes in skin is considered to function in wound repair (Saarialho-Kere et al., 2002). It is also elevated in cartilage from patients with osteoarthritis and rheumatoid arthritis (Kevorkian et al., 2004; Momohara et al., 2004). Overexpression of recombinant MMP-28 in lung adenocarcinoma cells induces irreversible epithelial mesenchymal transition, accompanied by cell surface loss of E-cadherin, processing of latent TGF $\beta$  complex and increased levels of TGF $\beta$ , along with up-regulation of MT1-MMP and MMP-9 and collagen invasive activity (Illman et al., 2006).

#### 4. Three-dimensional (3D) structures

Numerous 3D structures of MMPs have been determined both by X-ray crystallography and NMR spectroscopy (Maskos, 2005) including full-length proMMP-1 (Jozic et al., 2005), proMMP-2 (Morgunova et al., 1999) and the proMMP-2-TIMP-2 complex (Morgunova et al., 2002). Fig. 2 shows the structure of proMMP-2-TIMP-2 complex and individual domain structures. The overall polypeptide folds of propeptide domains, catalytic domains and hemopexin domains from other MMPs are essentially superimposable.

Structures have been solved for the propeptide domain of proMMP-1 (Jozic et al., 2005), proMMP-2 (Morgunova et al., 1999), proMMP-3 without the linker region and the hemopexin domain (Becker et al., 1995) and proMMP-9 without the linker region and the hemopexin domain (Elkins et al., 2002). The propeptide consists of three  $\alpha$  chains and connecting loops (Fig. 2). The proteinase susceptible 'bait region' is located between helix 1 and helix 2, but the structure of this region has not been resolved in the case of proMMP-1, proMMP-3 and proMMP-9 due to its flexible nature. This region of proMMP-2 is however stabilized by a disulphide bond. The 'cysteine switch' motif PRCGXPD in the propeptide is a signature of matrixins as all MMPs, except MMP-23, harbour this motif. The cysteine switch sequence lies in the substrate binding site, but the orientation of this segment is opposite from that of a peptide substrate. The SH group of the cysteine interacts with the catalytic zinc ion. Upon activation the interaction of Cys-Zn<sup>2+</sup> is disrupted, which allows a water molecule to bind to the zinc atom. The propeptide domains of MMPs may also play an important role in folding the proenzymes during synthesis.

The catalytic domain consists of a 5-stranded  $\beta$ -pleated sheet, three  $\alpha$ -helices and a connective loops (Fig. 2). It contains two zinc ions; one catalytic and one structural. Usually three calcium ions are found which are thought to stabilize the structure. MT1-MMP (MMP-14), MT2-MMP (MMP-15), MT3-MMP (MMP-16) and MT5-MMP (MMP-24) have a so-called MT loop, an additional 8 residues between  $\beta$ -strand II and III. This loop is critical for activation of proMMP-2 in the case of MT1-MMP (English et al., 2001). Binding of a peptide substrate to the enzyme is primarily dictated by the structure of the substrate binding site of the catalytic domain, including a pocket called the "S1 pocket" located to the right of the zinc atom. This pocket is hydrophobic in nature, but variable in depth depending on the MMP. It is therefore one of the determining factors of substrate specificity of MMPs. For protein substrate recognition, on the other hand, interaction with the non-catalytic domains is often required (see below). Binding of a substrate to the enzyme is thought to displace the water molecule from the zinc, and peptide bond hydrolysis is facilitated by the carboxylate group of the glutamate in the active site which draws a proton from the displaced water and allows a nucleophilic attack of the polarized water on the carbonyl carbon of the peptide bond.

Fibronectin type II (Fn II) domains are inserted in the loop between the fifth  $\beta$ -strand and the second helix of the catalytic domains of gelatinases (Fig. 2). The Fn II domains in MMP-2 and MMP-9 have a similar conformation. They consist of two antiparallel  $\beta$ -sheets connected with



a short  $\alpha$ -helix and stabilized by two disulfide bonds. However, the placements of the Fn II domains in the two gelatinases are significantly different. After superimposing the catalytic domains of proMMP-2 and proMMP-9, Fn II domain 1 and domain 3 fall roughly in the same places, but the position of domain 2 differs. Domain 2 of proMMP-2 has an area that interacts with the catalytic domain, but the corresponding domain of proMMP-9 is rotated and twisted away from the catalytic domain without making contacts (Elkins et al., 2002). Domain 3 in both progelatinases make contact with the propeptide and with the catalytic domain (Morgunova et al., 1999; Elkins et al., 2002).

The linker region connects the catalytic domain and the hemopexin domain. This region is considered to be flexible, as shown for MMP-9 (Rosenblum et al., 2007), but a number of prolines are found (Iyer et al., 2006; Jozic et al., 2005; Li et al., 1995; Morgunova et al., 1999). This suggests that this region may have some structural constraint suited for specific functions. Mutation of this region in MMP-1 (Tsukada and Pourmotabbed, 2002) and MMP-8 (Knäuper et al., 1997) reduced the collagenolytic activity, supporting the notion that the correct movement and arrangement between the catalytic domain and the hemopexin domain is important for this activity. Studies of MMP-9 and MMP-14 have found that the linker region can be extensively and heterogeneously N- and O-glycosylated and that these sugar chains have significant effects on the cellular biochemistry of these MMPs (Van den Steen et al., 2006; Wu et al., 2004).

The hemopexin domain has a 4-bladed  $\beta$ -propeller structure with a single disulfide bond between the first and the fourth blades (Fig. 2) (Gomis-Rüth et al., 1996; Li et al., 1995; Libson et al., 1995). Each blade is made up of four antiparallel  $\beta$ strands and the four  $\beta$ -sheets have similar scaffolds. The centre of the propeller generally contains one calcium ion and a chloride. The hemopexin domains are essential for collagenases to express their triple helical collagen degrading activity and for MT1-MMP to dimerize on the cell surface. The latter event is essential for MT1-MMP to activate proMMP-2 (Itoh et al., 2001) and to cleave collagen (Itoh et al., 2006).

## 5. Substrate specificity

The substrate specificity profiles of the MMPs have been defined either by identifying the cleavage sites of such protein substrates or by a series of synthetic peptide substrates (Nagase, 2001). More recent approaches include the use of phage display systems and proteomic screening (Overall and Blobel, 2007). In general, MMPs cleave a peptide bond before a residue (referred as the P1' residue) with a hydrophobic side chain, such as Leu, Ile, Met, Phe, or Tyr. The hydrophobic residues fit into the S1' specificity pocket of the enzyme, whose size and shape differ considerably among MMPs (Bode et al., 1999). In addition to the S1' pocket, other substrate contact sites (subsites) also participate in the substrate specificity of the enzyme (Nagase, 2001); particularly Pro in the P3 site (the third residue before the cleavage site) is generally favored by most MMPs.

### 5.1. The role of the extra-catalytic and non-catalytic domains of MMPs in substrate specificity

Ancillary non-catalytic domains of the matrixins play key roles for some MMPs to recognize their natural ECM substrates. The fibronectin type II domain of gelatinases are important for their effective cleavage of type IV collagen, elastin and gelatins, but they do not affect hydrolysis of small peptides (Murphy et al., 1994; Shipley et al., 1996a). Their interaction with specific ECM molecules allows the catalytic site to be oriented to the scissile peptide bond. For collagenases to cleave triple helical collagens their hemopexin domains are essential. Studies by Chung et al. (2004) have demonstrated that collagenases locally unwind the triple helical collagen chains before they cleave the peptide bonds. It is postulated that the collagen binding groove consists of the catalytic domain and the hemopexin domain. In the case of

proMMP-1, the prodomain interacts with both the catalytic and hemopexin domains (Jozic et al., 2005), rendering it in a 'closed' configuration of proMMP-1 and the pro-domain partially blocks the putative collagen binding site. The removal of the pro-domain upon activation opens the groove ('open' form) and allows collagenases to bind to collagen (Iyer et al., 2006; Li et al., 1995). This explains the earlier reports that proMMP-1 does not bind to collagen I, but the activated collagenase does (Allan et al., 1991; Welgus et al., 1985). Nevertheless, it is not yet known how collagenases unwind the triple helical strands. Effective unwinding may require cooperative molecular interactions between collagenase and the triple helical substrate.

ProMMP-2 forms a complex with TIMP-2. This is due to a tight binding between the hemopexin domain of the proenzyme and the non-inhibitory C-terminal domain of the inhibitor. This complex formation is essential for proMMP-2 activation by MT1-MMP on the cell surface, which requires a quaternary molecular complex (Itoh and Seiki, 2005). Because the proMMP-2-TIMP-2 complex can inhibit active MMPs, the complex binds to an active MT1-MMP on the cell surface through the free N-terminal MMP inhibitory domain of TIMP-2. This presumably orients the propeptide of proMMP-2 to an adjacent active MT1-MMP, and the specific reaction of two MT1-MMP molecules is driven by the hemopexin domains. TIMP-3 and TIMP-4 form a complex with proMMP-2 in a similar manner to TIMP-2 and the proMMP-2-TIMP-4 complex interacts with MT1-MMP, but it is non-productive in terms of MMP-2 activation (Bigg et al., 2001). The biological significance of the proMMP-2-TIMP-3 complex is not known.

The hemopexin domain of proMMP-9 can also bind to TIMP-1 and TIMP-3 through their C-terminal domains. ProMMP-9 in neutrophils partially binds to neutrophil gelatinase associated lipocalin-like molecule (NGAL) through an intermolecular disulfide bond (Kjeldsen et al., 1993). However, the biological significance of these complexes is not clear, except that proMMP-9-TIMP complexes inhibit metalloproteinases and activation of proMMP-9 of the complex by MMPs is restricted.

## 6. Metalloproteinase inhibitors

### 6.1. Endogenous inhibitors of MMPs

$\alpha_2$ -Macroglobulin and tissue inhibitors of metalloproteinases (TIMPs) are two major inhibitors of MMPs. Human  $\alpha_2$ -macroglobulin is a glycoprotein of 725 kDa consisting of four identical subunits of 180 kDa. It acts as a general proteinase inhibitor and is found in the blood and in tissue fluids. Most endopeptidases, regardless of their class, are inhibited by entrapping the enzyme within the macroglobulin (Barrett and Starkey, 1973). The complex is then rapidly cleared by the low density lipoprotein receptor-related protein-1-mediated endocytosis (Strickland et al., 1990). MMP activities in the fluid phase are mainly regulated by  $\alpha_2$ -macroglobulin and related proteins.

TIMPs were originally found as collagenase inhibitors in serum and in the conditioned medium from fibroblast cultures (Vater et al., 1979; Welgus et al., 1979). There are four TIMPs in humans (TIMP-1 to -4) of 22–29 kDs. TIMP-1 and TIMP-3 are glycoproteins and TIMP-2 and TIMP-4 do not contain carbohydrates. They inhibit all MMPs tested so far, but TIMP-1 is a poor inhibitor of MT1-MMP, MT3-MMP, MT5-MMP and MMP-19 (Baker et al., 2002). Recent studies have shown that TIMPs can inhibit a broader spectrum of metalloproteinases. For example, TIMP-1 inhibits ADAM-10 (Amour et al., 2000), whilst TIMP-2 inhibits ADAM12 (Jacobsen et al., 2008). TIMP-3 has a much broader inhibition profile including ADAM-10 (Amour et al., 2000), -12 (Jacobsen et al., 2008) and -17 (Amour et al., 1999) and ADAMTSs (ADAMTS-1, -2, -4 and -5) (Kashiwagi et al., 2001; Rodriguez-Manzanique et al., 2002; Wang et al., 2006). Because of this broad inhibitory spectrum, TIMP-3 ablation in mice causes lung emphysema-like alveolar damage (Leco et al., 2001) and faster apoptosis of

mammary epithelial cells after weaning (Fata et al., 2001), whereas TIMP-1-null mice and TIMP-2-null mice do not exhibit obvious abnormalities unless those animals are challenged. This indicates that TIMP-3 is a major regulator of metalloproteinase activities *in vivo*.

Several other proteins have been reported to inhibit selected members of MMPs: a secreted form of  $\beta$ -amyloid precursor protein inhibits MMP-2 (Higashi and Miyazaki, 2003); A C-terminal fragment of procollagen C-proteinase enhancer protein inhibits MMP-2 (Mott et al., 2000); and RECK, a GPI-anchored glycoprotein that suppresses angiogenesis inhibits MMP-2, MMP-9 and MMP-14 (Oh et al., 2001). However, the mechanisms of action of these proteins are not known. Tissue factor pathway inhibitor-2, a serine proteinase inhibitor, was reported to inhibit MMP-1 and MMP-2 (Herman et al., 2001), but this effect could not be confirmed (Du et al., 2003).

## 6.2. Inhibition mechanism of TIMPs and TIMP variants

The primary structure of TIMP-1 was deduced from cDNA sequencing (Docherty et al., 1985). There are four TIMPs which are homologous to each other and consisting of 184–194 amino acids with 12 conserved cysteines. The determination of the six disulfide bond arrangement of TIMP-1 indicated that it consists of an N-terminal domain and a C-terminal domain, each containing three disulfide bonds (Williamson et al., 1990). The N-terminal domain alone is fully functional for MMP inhibition (Murphy et al., 1991). The first 3D structure was solved for the N-terminal domain of TIMP-2 by NMR spectroscopy and revealed of a  $\beta$ -barrel structure with oligosaccharide–oligonucleotide binding (OB)-fold and two small  $\alpha$ -helices at the C-terminal end (Williamson et al., 1994), but it did not show how TIMP-2 interacts with MMPs. A possible MMP binding site of TIMP-1 was first proposed to be around Val69-Cys70, based on the observation that the Val69-Cys70 bond was cleaved by neutrophil elastase which inactivated TIMP-1, but this cleavage was protected in the TIMP-1-MMP-3 complex (Nagase et al., 1997). The NMR structure of N-TIMP-2 showed that Val69 is a part of exposed ridge-like structure formed with the N-terminal segment of the inhibitor where Cys1 and Cys70 are linked by disulfide bond. Mutagenesis around the ridge region altered the reactivity of TIMP-1 with MMPs, which further supported that this region might be the MMP reactive site in the TIMPs (Huang et al., 1997). The exact mechanism by which TIMP inhibit MMPs had to wait for the crystal structures of the TIMP-1-MMP-3 catalytic domain complexes (Gomis-Rüth et al., 1997), which showed that the N-terminal four residues Cys1-Thr-Cys-Val4 and the residues Glu67-Ser-Val-Cys70 that are linked by a disulfide bond slots into the active site of the MMPs (Fig. 3A). The catalytic zinc atom of MMP-3 is bidentately chelated by the N-terminal amino group and the carbonyl group of Cys1, which expels the water molecule bound to the zinc atom (Fig. 3B). This region occupies about 75% of the protein–protein interaction in case of the complex of the catalytic domain of MMP-3 and TIMP-1 and the side chain of Thr2 enter into the S1' pocket of the enzyme. The crystal structure of TIMP-2-MMP-14 catalytic domain showed a similar complex formation as TIMP-1 and MMP-3, but TIMP-2 has a longer AB loop (see Fig. 4) which make additional contact with MMP-14 (Fernandez-Catalan et al., 1998).

The structural information on TIMP-MMP complexes led to further mutagenesis studies to address the nature of the specificity of TIMPs. The residues in TIMP-1 and TIMP-2 which showed significant changes in inhibition specificity upon mutagenesis are highlighted in Fig. 4. Mutation of the position 2 (Thr in TIMP-1) greatly affected the affinity of TIMPs for MMPs, but there was a very poor correlation in residues that affect inhibition potency and substrate specificity for different MMPs (Meng et al., 1999). Substitution to glycine essentially inactivated TIMP-1 to inhibit MMPs (Meng et al., 1999). Additional mutations at position Val4 and Ser68 and their combination generated inhibitors discriminatory between MMP-1, -2 and -3 (Wei et al., 2003), indicating that MMP reactive ridge may be modified to make TIMPs



selective. Ile35, Tyr36 and Asn38, located in the longer AB loop of TIMP-2, fit into a special cavity on the surface of the MMP-14 molecule and mutation of Tyr36 indicated that it is a key residues for this interaction (Williamson et al., 2001).

There are several studies which represent gain of function mutagenesis. TIMP-1 is a poor inhibitor of MT1-MMP, MMP-19 and tumor necrosis factor  $\alpha$  converting enzyme (TACE/ADAM17), but it gains reactivity for all three metalloproteinases by replacing Thr98 with Leu, which is found in both TIMP-2 and TIMP-3 (Lee et al., 2003, 2004a), and further improved with replacement of the AB loop (Lee et al., 2004a). TIMP-2 does not inhibit TACE, but it was also converted to a functional inhibitor by replacing key residues of the AB loop with those of TIMP-3, in combination with S2T/A70S/V71L mutation (Lee et al., 2004b). Full-length TIMP-4 is a weak inhibitor of TACE, but truncation of the C-terminal domain increased the reactivity and replacement with the TIMP-3 AB loop further improved the inhibitory activity with a sub-nanomolar  $K_i$  (Lee et al., 2005).

The importance of chelation of the N-terminal amino group of TIMPs to the catalytic zinc ion of the MMPs, was confirmed by carbamylation of the N-terminus (Higashi and Miyazaki, 1999), or addition of an extra Ala at the N-terminus (Wingfield et al., 1999), both of which inactivated the TIMPs with respect to MMP inhibition. However, Wei et al. (2005) have reported that addition of Ala to the N-terminus of TIMP-3 did not significantly alter the ability to inhibit ADAM-17, although it impaired the inhibition of MMPs. Mutation of Thr2 of TIMP-3 to Gly also inactivated TIMP-3 to inhibit MMPs, but retained the inhibitory activity for ADAM17. Those studies suggest that ADAM inhibition mechanism by TIMP-3 may be different from that for MMPs. The 3D structure of the complex formed between TIMP-3 with an extra Ala at its N-terminus and ADAM17 would provide new insights into this interaction.

### 6.3. Other biological activities of TIMPs

When TIMP-1 was cloned its identity with the protein having erythroid potentiating activity (EPA) became apparent (Docherty et al., 1985; Gasson et al., 1985). Later, TIMP-2 was also shown to have EPA (Stetler-Stevenson et al., 1992). Hayakawa et al. (1992, 1994) reported that TIMP-1 and TIMP-2 have cell growth promoting activity for many types of cells, which may explain the EPA properties of TIMP-1 and TIMP-2. Both TIMPs also protect cells from apoptosis (Valente et al., 1998; Guedez et al., 1998). On the other hand, TIMP-3 causes apoptosis of tumor cells and smooth muscle cells (Ahonen et al., 2003; Baker et al., 1998; Smith et al., 1997). This activity is thought to be due to the inhibition of TACE which prevents the shedding of cell death receptors such as Fas, tumor necrosis factor receptor-1 and TNF-related apoptosis inducing ligand receptor-1 (Ahonen et al., 2003). TIMP-3 can also bind to vascular endothelial growth factor (VEGF) receptor 2 and inhibits downstream signalling of VEGF and angiogenesis (Qi et al., 2003). The phenotypes of *TIMP-3* null mice have largely been ascribed to the loss of metalloproteinase function but there is clearly a need to be aware of other non-inhibitory functions of all the TIMPs.

### 6.4. Synthetic inhibitors of matrix MMPs

The development of synthetic inhibitors of MMPs initially relied on the use of a peptide sequence recognized by the targeted protease, to which a chelating moiety is introduced to interact with the zinc ion of the active site. This strategy generated several potent non-peptidic inhibitors of metalloproteinases, but one drawback of this approach has been the poor selectivity displayed by this class of inhibitors. Despite knowledge of the three-dimensional structure of numerous catalytic domains of metalloproteinases, the development of highly specific synthetic active-site-directed inhibitors of metalloproteinases that discriminate members of the matrixin family remains a challenge. Due to the nature of MMP active sites, the development of specific MMP inhibitors will need to combine sophisticated theoretical and

experimental approaches to identify the specific structural features of each individual metalloproteinase that can be exploited to obtain the desired selectivity. Site specific delivery is also a worthwhile goal and may permit the use of inhibitors with lower in vitro potency.

The majority of the clinical trials using synthetic metalloproteinase inhibitors were conducted with cancer patients and proved unsuccessful, principally due to the lack of efficacy and untoward side effects including musculoskeletal pain and tendonitis in some cases (Milner and Cawston, 2005). In animal models metalloproteinase inhibitors have been relatively effective in preventing development and progression of early disease, but have had little effect on advanced disease. Hence their poor performance is unsurprising given the design of the trials that have been undertaken to date (Coussens et al., 2002), many of which involved the use of MMP inhibitors as single agent therapies for patients with advanced disease. It is clear that a more detailed knowledge of the roles of the metalloproteinases in each disease and their spatiotemporal expression are needed to guide the development and use of inhibitors of clinical value. This would need to be coupled with the development of robust markers to detect efficacy.

New generation variants of the hydroxamate based inhibitors which are relatively more specific are now being evaluated (Fisher and Mobashery, 2006). Newer trends in inhibitor design are also in evidence, due to concerns about the metabolism of hydroxamates and the ability to chelate other metalloproteins. Thiol, hydroxypyronone and barbiturate based inhibitors have been described, as well as phosphinates which act as transition state analogues. Tetracycline based inhibitors appear to have some efficacy which is hard to explain on the basis of their weak MMP binding and may be due to effects on MMP synthesis. It is clear that MMP inhibitors could be extremely efficacious as therapeutics in a number of diseases but the design criteria are very demanding. Good selectivity for the target MMP, correct spatial and temporal administration and appropriate dosage regimes all need to be fulfilled.

### 6.5. Novel approaches to metalloproteinase inhibition

Alternative strategies for the development of metalloproteinase inhibitors are being considered (Overall and Lopez-Otin, 2002). The production of specific antibody fragments developed from phage library screens could be promising. Such proteins could target the active site in a more specific way than chemical inhibitors. They may also be used to define exo sites on the metalloproteinases that determine their substrate specificity or extracellular location. For instance, the hemopexin domain of the collagenase, MMP-1, is essential for the specificity of the catalytic domain cleavage of collagen. MMP-2 is localized to specific extracellular collagenous sites by its fibronectin domains and MT1-MMP (MMP-14) requires the hemopexin domain for cell surface clustering as part of its collagenolytic capacity and ability to mediate proMMP 2 activation. The hemopexin domain also determines its binding to CD44 (Suenaga et al., 2005). Further understanding of the nature of these interactions will allow the development of either specific chemical antagonists of binding or of fragment antibodies that target these interactions. Several other strategies may potentially downregulate metalloproteinases. Both the intracellular signalling pathways and the downstream transcription factors which induce gene expression are being intensively studied. Blockade of mitogen activated protein kinase (MAPK) pathways, nuclear factor (NF)- $\kappa$ B or activator protein(AP)-1 have all been shown to have some efficacy in vitro or in animal models of arthritis (Mix et al., 2004). The use of biological reagents to block inflammatory cytokines also reduces metalloproteinase expression in many cases. The tetracyclines, which are rather weak inhibitors of MMP catalytic activity, also influence on their synthesis and have been successfully trialed in rheumatoid arthritis (Voils et al., 2005). Gene therapy, either overexpressing TIMPs or using cytokines/growth factors, has been successful in animal models and may have future uses once the problems of the safe and efficient delivery of genes into target cells and tissues have been overcome (Van der Laan et al., 2003).

## 7. MMP pathophysiology

The expression of MMPs has been documented during many stages of mammalian development, from embryonic implantation (Harvey et al., 1995) to the morphogenesis of specific tissues, including lung, bone and mammary gland (reviewed by Vu and Werb, 2000; Page-McCaw et al., 2007). Other physiological processes, including growth and wound healing (Ravanti and Kähäri, 2000), also involve the expression of abundant MMPs in specific spatial and temporal locations. Similarly, many disease processes show specific patterns of MMP expression, such as cancer (reviewed by (Sternlicht and Werb, 2001; Egeblad and Werb, 2002), cardiovascular disease (Newby, 2005) and arthritis (Milner and Cawston, 2005; Burrage and Brinckerhoff, 2007; Murphy and Nagase, 2008). Many animal models of disease have been developed and studied with respect to the relevance of MMPs in disease progression. Such studies have reiterated the observation that the relevance of MMP expression profiles varies with the nature of the cells, the stage of the disease and the genetic make up of the animal (Hu et al., 2007; Lemaitre and D'Armiento, 2006; Martin and Matrisian, 2007).

Inactivation of specific genes in mice has presented a rather different picture. With very few exceptions, embryogenesis and subsequent growth have been relatively normal, indicating the potential for both compensatory effects of MMP function and adaptive development. However, pathological challenges to the system have proved fruitful in promoting the understanding of the roles of MMPs. Table 2 gives examples of the roles of MMPs in the mouse models of cancer, cardiovascular disease and arthritis. For example, deficiency of MMP-7 decreased the development of tumors in a mouse model of human cancer (Wilson et al., 1997). Over-expression of MMPs in mice has also been useful; excess MMP-1 in the heart caused functional defects due to the reduction in collagen (Kim et al., 2000) and overexpression of MMP-3 in the mammary gland leads to spontaneous pre-malignant lesions and the development of cancers (Sternlicht et al., 1999).

### 7.1. MMPs and cancer

A number of cancer studies have correlated MMP expression and disease outcome (comprehensively documented by Egeblad and Werb, 2002). MMPs can contribute to tumor growth not only by degradation of the ECM but by the release of sequestered growth factors or the generation of bioactive fragments (Noel et al., 2008). For instance, MMP-9 mobilizes VEGF from the ECM (Bergers et al., 2000) and cleaves type IV collagen to generate tumstatin, an angiogenesis inhibitor (Hamano et al., 2003). MMPs are also important in tumor progression, promoting invasion, immune escape and many other events. However, particularly in carcinomas, MMPs are associated with the supporting 'host' cells rather than the tumor cells (Noel et al., 2008) and this finding has emphasized the emerging theme of the importance of the microenvironment in tumorigenesis. The task of determining the specific role of individual enzymes in each case is hence somewhat daunting. However, the widespread use of both gene and tissue microarrays is generating informative data. For example, Minn et al. (2007) identified a set of genes, including MMP-1 and MMP-2 that mediate breast cancer metastasis to lungs in human patients using careful transcriptomic analyses coupled with functional verification and clinical validation. Acuff et al. (2006) used a customized Affymetrix protease microarray (Hu/Mu ProtIn chip) designed to distinguish human and mouse genes to analyze the expression of proteases and protease inhibitors in lung cancer. Using an orthotopic lung cancer model, they showed that murine MMP-12, MMP-13 and cathepsin K were up-regulated in tumor tissue compared with normal mouse lung. To determine the relevance of stromal proteases detected using this model system, they compared the results to an analysis of human lung adenocarcinoma specimens using Affymetrix microarray. MMP-12, MMP-13 and cathepsin K showed an increase in expression in human tumors compared with normal lung similar to that seen in the orthotopic model. Immunohistochemical analysis also confirmed

MMP-12 expression in the stroma of human lung tumor samples. MMP-14 (MT1-MMP) deficient mice have been crossed with the MMTV-polyoma virus middle T antigen mice (PyMT) to evaluate its significance in this tumorigenesis model. MMP-14 deficient tumors grew to the experimental endpoint more quickly, but demonstrated a reduced ability to metastasize to the lungs (Itoh et al., 2001).

The ablation of individual MMP and TIMP genes in mice and the study of the subsequent effects on tumorigenesis has become a standard approach to the analysis of their functions; some examples are listed in Table 2. It is notable that animal studies have shown that MMPs sometimes have 'protective' roles in cancer development. *Mmp8*-null male or ovariectomized female mice develop significantly larger numbers of skin papillomas after a chemical carcinogen treatment (Balbin et al., 2003) and higher grade and more aggressive skin tumors developed in *Mmp9*-null mice (Coussens et al., 2000). In a human study of MMP-12 in squamous cell carcinoma it was found that high expression in tumor cells was associated with more aggressive tumors and high expression in tumor macrophages was correlated with lower grade tumors (Kerkelä et al., 2002). It is possible that obtaining a detailed understanding of the potential role of MMPs in the different cell types associated with tumors may be vital for the design of therapeutic anti-MMP strategies.

## 7.2. MMPs and vascular disease

It is well accepted that MMPs are key players in most vascular diseases and a similar elucidation of the spectrum of expression and specific roles has to be effected before a therapeutic opportunity can be clearly identified (Galis and Khatri, 2002; Newby, 2005; Newby and Johnson, 2005). MMPs have been implicated in intimal thickening, a repair response to damage of the walls of large arteries in human atherosclerotic pathologies, as well as in the subsequent plaque rupture. Hence, the concept of 'good' and 'bad' MMPs can be invoked in cardiovascular disease as in cancer, but the existing data from animal model studies are not clear cut. Studies using MMP gene knockout mice have indicated that MMP-2 and MMP-9 play key roles in cardiac rupture after myocardial infarction (Hayashidani et al., 2003; Heymans et al., 1999; Matsumura et al., 2005a,b; Romanic et al., 2002a; Romanic et al., 2002b; Romanic et al., 2002c). A recent study showed that MT1-MMP (MMP-14) is increased after ischemia-reperfusion (Deschamps et al., 2005). TIMP-3 deficiency in mice disrupted matrix homeostasis and caused spontaneous left ventricular dilation, cardiomyocyte hypertrophy and contractile dysfunction (Fedak et al., 2004). A critical role of MMP-2 and MMP-9 has been also shown for the development of abdominal aortic aneurysm using MMP gene deletion mice (Longo et al., 2002). Recent studies on atherosclerotic plaque stability using a series of apoE/MMP double knockout mice have indicated that MMP-3 and MMP-9 have protective roles by limiting plaque growth and enhancing plaque stability, but MMP-12 promotes lesion expansion and destabilization (Johnson et al., 2005). Chase and Newby (Chase and Newby, 2003) have proposed that multiple steps of MMP gene induction occur in vascular pathologies due to the progressive recruitment of different cell types and inductive factors during different phases of the disease. A widening spectrum of MMPs, starting with MMP-2 and MMP-9, leading to MMP-1, MMP-12 and MMP-14, followed by MMP-3, MMP-11 and MMP-13 ultimately leads to a transition from matrix turnover to matrix destruction.

## 7.3. MMPs and arthritis

The expression of matrix metalloproteinases in synovial membranes, cartilage, tendon and bone of synovial joints in both rheumatoid arthritis (RA) and osteoarthritis (OA) is well documented and often correlates with tissue destruction (Smeets et al., 2001; Murphy et al., 2002; Murphy and Nagase, 2008). As for other diseases, the spectrum of these enzymes orchestrating not only connective tissue turnover but other aspects of tissue biology, is much larger than anticipated. In both diseases, inflammatory mediators stimulate the production of

MMPs that degrade most components of the extracellular matrix. The collagenases, MMP-1 and MMP-13 are produced by synovial fibroblasts and macrophages and chondrocytes and have important roles in RA and OA because they are rate limiting in the process of collagen degradation. Antibodies that recognize terminal amino acid sequences generated by proteolysis at specific sites in type II collagen have been invaluable for identifying the proteinases responsible for cartilage breakdown both in vitro and in vivo (Hollander et al., 1994; Wu et al., 2002). Preliminary results with quantitative assays of type II collagen neoepitopes suggest that they may be useful markers of joint disease in humans (Fosang et al., 2003). MMP-8 and MMP-14 are collagenases and are also expressed by cells within synovial joints, but their precise contribution to collagen degradation has not yet been established. MMP-13 also degrades the proteoglycan molecule, aggrecan, giving it a dual role in matrix destruction. MMPs such as MMP-2, MMP-3, MMP-9, MMP-10 and MMP-19 are also elevated in arthritis and, along with MMP-13 these enzymes degrade non-collagen matrix components of the joints (Cawston and Wilson, 2006). Many MMPs have been associated with bone matrix turnover, involving virtually all the cell types present. Collagenolytic MMPs have a role in the actions of the bone forming cells, the osteoblasts, but the major collagenolytic proteinase in osteoclastic bone resorption appears to be the cysteine proteinase, cathepsin K which can function in the acidic phagolysosomal resorption zone of the osteoclast. However, MMPs do play a role in osteoclastic resorption in pathological conditions, including MMP-1, MMP-2, MMP-3, MMP-9, MMP-12, MMP-3 and MMP-14 (Andersen et al., 2004). They degrade a number of the non-collagenous proteins of the bone matrix and clearly play roles beyond ECM cleavage.

#### 7.4. Genetic disorders of MMPs and TIMPs

Only a few human genetic disorders of the MMPs and TIMPs have been described in relation to human disease. An autosomal recessive disorder, multicentric osteolysis or 'vanishing' bone syndrome resulting from inactivating mutations in the *Mmp2* gene has been described (Martignetti et al., 2001). Mosig et al. (2007) have also shown that the loss of MMP-2 in mice disrupts skeletal and craniofacial development due to defects in osteoblast and osteoclast growth. A missense mutation in the *MMP13* gene, spondyloepimetaphyseal dysplasia, Missouri type, causes an autosomal dominant disorder characterized by defective growth and remodelling of long bones (Kennedy et al., 2005). In comparison, *Mmp13*-null mice have defects in growth plate cartilage with increased hypertrophic domains and delayed endochondral ossification during development (Inada et al., 2004; Stickens et al., 2004). An *MMP20* gene mutation in the splice acceptor site of intron 6 was shown to link to autosomal recessive pigment hypomaturation amelogenesis imperfecta (Kim et al., 2005). This mutation is postulated to cause either a loss of the functional hemopexin domain or reduction of MMP-20 caused by degradation of its mRNA.

Sorsby's fundus dystrophy (SFD) is a rare autosomal dominant disorder that results in degeneration of the macular region of the retina, with onset usually in the fourth to fifth decade of life. It leads to the rapid loss of central vision, often followed by further loss of peripheral vision. SFD has been shown to be a single-gene disorder, linked to mutations in exon 5 of the tissue inhibitor of metalloproteinases 3 (TIMP3) gene on chromosome 22q12-q13 (Apte et al., 1994).

#### 7.5. MMP and TIMP regulation in relation to disease

Studies on translational and post-translational regulation of the MMP family have focussed largely on the understanding of tissue specific expression. From promoter studies through to the role of specific growth factors, signalling pathways and transcription factors, some idea of the intricacies of regulation are emerging (Yan and Boyd, 2007). Functional polymorphisms derived from nucleotide insertions, substitutions or micro-satellite instability have been reported in several MMP promoters and have been shown to contribute to inter-individual



susceptibility and outcome in several cardiovascular diseases including coronary artery disease, stenosis, myocardial infarction, coronary aneurysm, stroke, large artery stiffness (Ye, 2000; Newby and Johnson, 2005; Abilleira et al., 2006). The clinical impact of such polymorphisms in gastric cancer (Kubben et al., 2006) and in breast cancer progression (Hughes et al., 2007) are examples from cancer studies. Variation in *MMP3*, *MMP7*, *MMP12* and *MMP13* genes has been found to be associated with functional status in rheumatoid arthritis (Ye et al., 2007) and specific haplotypes of the *MMP1* and *MMP3* genes associate with radiographic joint destruction (Dörr et al., 2004).

Both DNA methylation and altered chromatin structure contribute to the epigenetic regulation of MMP and TIMP gene expression. Hypo- or hypermethylation of *MMP2*, *MMP3*, *MMP9* and *MMP10* have been described in different tumor types (Yan and Boyd, 2007). Nakamura et al. (2005) found that frequent hypermethylation of a locus at 22q12.3 correlated with loss of TIMP-3 expression in secondary glioblastoma. This epigenetic change was significantly correlated to poor survival in patients with grade II diffuse astrocytoma.

## 8. Conclusions and perspectives

The potential involvement of any of the 23 MMPs in both normal tissue maintenance and the destructive or reparative aspects of many diseases has produced many challenges when considering the potential application of MMP inhibitors as therapeutic agents. A detailed understanding of MMP expression patterns, in terms of both cellular origins and timing is a necessity. Furthermore, some knowledge of the precise role of an individual MMP within each context is important. This needs to be coupled with the ability to generate specific inhibitors, either targeting the active site or other interaction sites. Like all molecularly targeted cytostatic agents, there is a need for good clinical evaluation of efficacy in the form of appropriate biomarkers and therapeutic endpoints. The recent developments in techniques for imaging active MMPs will prove useful in this regard. Imaging of the cleavage of near infra red fluorescent substrates allows the visualization of the expression and activity of MMPs, as well as their influence on the tumor via imaging based biomarkers (Weissleder, 2006). Novel MMP-7 substrates have also recently been described for MRI imaging. These are based on the concept of a solubility switch on proteolysis to act as a product trap (Lepage et al., 2007). Cleavage of MMP substrates can also be utilized in photodynamic therapies where a non-toxic agent becomes both fluorescent and releases toxic singlet oxygen upon proteolysis (Choi et al., 2006).

## Acknowledgments

We thank Rob Visse for preparing illustrations of three-dimensional structures of MMPs and TIMPs. This work was supported by grants from the Cancer Research UK, Medical Research Council, European Union Framework 5 Program and 6 Program to G.M., and from Wellcome Trust, Arthritis Research Campaign and National Institutes of Health (AR40994) to H.N.

## References

- Abilleira S, Bevan S, Markus HS. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. *J Med Genet* 2006;43 (12):897–901. [PubMed: 16905683]
- Acuff HB, Sinnamon M, Fingleton B, Boone B, Levy SE, Chen X, Pozzi A, Carbone DP, Schwartz DR, Moin K, Sloane BF, Matrisian LM. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. *Cancer Res* 2006;66 (16):7968–7975. [PubMed: 16912171]
- Ahokas K, Lohi J, Illman SA, Llano E, Elomaa O, Impola U, Karjalainen-Lindsberg ML, Saarialho-Kere U. Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-

- regulated by transforming growth factor-beta1 in keratinocytes. *Lab Invest* 2003;83 (12):1887–1899. [PubMed: 14691307]
- Ahonen M, Poukkula M, Baker AH, Kashiwagi M, Nagase H, Eriksson JE, Kähäri VM. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. *Oncogene* 2003;22 (14):2121–2134. [PubMed: 12687014]
- Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. *J Biol Chem* 1995;270 (11):5872–5876. [PubMed: 7890717]
- Allan JA, Hembry RM, Angal S, Reynolds JJ, Murphy G. Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain. *J Cell Sci* 1991;99 (Pt 4):789–795. [PubMed: 1770006]
- Amour A, Hutton M, Knäuper V, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Docherty AJ, Murphy G. Inhibition of the metalloproteinase domain of mouse TACE. *Ann N Y Acad Sci* 1999;87:728–731. [PubMed: 10415820]
- Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knäuper V, Docherty AJP, Murphy G. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. *FEBS Lett* 2000;473 (3):275–279. [PubMed: 10818225]
- Andersen TL, del Carmen OM, Kirkegaard T, Lenhard T, Foged NT, Delaisse JM. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. *Bone* 2004;35 (5):1107–1119. [PubMed: 15542036]
- Apte SS, Mattei MG, Olsen BR. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. *Genomics* 1994;19 (1):86–90. [PubMed: 8188246]
- Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro – TIMP-3 promotes apoptosis. *J Clin Invest* 1998;101 (6):1478–1487. [PubMed: 9502791]
- Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. *J Cell Sci* 2002;115 (Pt 19):3719–3727. [PubMed: 12235282]
- Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, Overall CM, Shapiro SD, Lopez-Otin C. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. *Nat Genet* 2003;35 (3):252–257. [PubMed: 14517555]
- Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan I, Pennington CJ, Bourgoin P, Edwards DR, Yong VW. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. *Brain* 2003;126 (Pt 12):2738–2749. [PubMed: 14506071]
- Barrett AJ, Starkey PM. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. *Biochem J* 1973;133 (4):709–724. [PubMed: 4201304]
- Bartlett JD, Beniash E, Lee DH, Smith CE. Decreased mineral content in MMP-20 null mouse enamel is prominent during the maturation stage. *J Dent Res* 2004;83 (12):909–913. [PubMed: 15557396]
- Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald PM, Cameron PM, Esser CK, Hagmann WK, Hermes JD, Springer JP. Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. *Protein Sci* 1995;4 (10):1966–1976. [PubMed: 8535233]
- Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. *Nature Cell Biol* 2000;2 (10):737–744. [PubMed: 11025665]
- Bigg HF, Morrison CJ, Butler GS, Bogoyevitch MA, Wang ZP, Soloway PD, Overall CM. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type I-matrix metalloproteinase. *Cancer Res* 2001;61 (9):3610–3618. [PubMed: 11325829]
- Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K. Structural properties of matrix metalloproteinases. *Cell Mol Life Sci* 1999;55 (4):639–652. [PubMed: 10357232]

- Bode W, Gomis-Rüth FX, Stöcker W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. *FEBS Lett* 1993;331 (1–2):134–140. [PubMed: 8405391]
- Burrage PS, Brinckerhoff CE. Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. *Curr Drug Targets* 2007;8 (2):293–303. [PubMed: 17305507]
- Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. *Crit Rev Biochem Mol Biol* 2007;42 (3):113–185. [PubMed: 17562450]
- Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. *Best Pract Res Clin Rheumatol* 2006;20 (5):983–1002. [PubMed: 16980219]
- Chase AJ, Newby AC. Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. *J Vasc Res* 2003;40 (4):329–343. [PubMed: 12891002]
- Choi Y, Weissleder R, Tung CH. Selective antitumor effect of novel protease-mediated photodynamic agent. *Cancer Res* 2006;66 (14):7225–7229. [PubMed: 16849570]
- Chung L, Dinakarandian D, Yoshida N, Lauer-Fields JL, Fields GB, Visse R, Nagase H. Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. *EMBO J* 2004;23 (15):3020–3030. [PubMed: 15257288]
- Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. *Cell* 2000;103 (3):481–490. [PubMed: 11081634]
- Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. *Science* 2002;295 (5564):2387–2392. [PubMed: 11923519]
- Creemers EE, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, Hauet AM, Escobar PG, Cleutjens JP, Smits JF, Daemen MJ, Zile MR, Spinale FG. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. *Am J Physiol Heart Circ Physiol* 2003;284 (1):H364–H371. [PubMed: 12388239]
- Cruz-Munoz W, Sanchez OH, Di Grappa M, English JL, Hill RP, Khokha R. Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3(–/–) mice. *Oncogene* 2006;25 (49):6489–6496. [PubMed: 16702949]
- Davidson ML, Wurtz SO, Romer MU, Sorensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brunner N, Lademann U. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. *Br J Cancer* 2006;95 (8):1114–1120. [PubMed: 17047657]
- Deschamps AM, Yarbrough WM, Squires CE, Allen RA, McClister DM, Dowdy KB, McLean JE, Mingoa JT, Sample JA, Mukherjee R, Spinale FG. Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. *Circulation* 2005;111 (9):1166–1174. [PubMed: 15723986]
- Docherty AJP, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJR, Murphy G, Reynolds JJ. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. *Nature* 1985;318 (6041):66–69. [PubMed: 3903517]
- Dörr S, Lechtenbohrer N, Rau R, Herborn G, Wagner U, Müller-Myhsok B, Hansmann I, Keyszer G. Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis. *Arthritis Res Ther* 2004;6 (3):R199–R207. [PubMed: 15142265]
- Du X, Chand HS, Kisiel W. Human tissue factor pathway inhibitor-2 does not bind or inhibit activated matrix metalloproteinase-1. *Biochim Biophys Acta* 2003;1621 (3):242–245. [PubMed: 12787920]
- Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. *J Clin Invest* 2000;106 (1):55–62. [PubMed: 10880048]
- Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer* 2002;2 (3):161–174. [PubMed: 11990853]
- Elkins PA, Ho YS, Smith WW, Janson CA, D'Alessio KJ, McQueney MS, Cummings MD, Romanic AM. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix

- metalloproteinase. *Acta Crystallogr D Biol Crystallogr* 2002;58 (Pt 7):1182–1192. [PubMed: 12077439]
- English WR, Holtz B, Vogt G, Knäuper V, Murphy G. Characterization of the role of the “MT-loop” – An eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases. *J Biol Chem* 2001;276 (45):42018–42026. [PubMed: 11555661]
- Fata JE, Leco KJ, Voura EB, Yu HY, Waterhouse P, Murphy G, Moorehead RA, Khokha R. Accelerated apoptosis in the Timp-3-deficient mammary gland. *J Clin Invest* 2001;108 (6):831–841. [PubMed: 11560952]
- Fedak PW, Smookler DS, Kassiri Z, Ohno N, Leco KJ, Verma S, Mickle DA, Watson KL, Hojilla CV, Cruz W, Weisel RD, Li RK, Khokha R. TIMP-3 deficiency leads to dilated cardiomyopathy. *Circulation* 2004;110 (16):2401–2409. [PubMed: 15262835]
- Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, Tschesche H, Maskos K. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase a receptor. *EMBO J* 1998;17 (17):5238–5248. [PubMed: 9724659]
- Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. *Cancer Metastasis Rev* 2006;25 (1): 115–136. [PubMed: 16680577]
- Fosang AJ, Stanton H, Little CB, Atley LM. Neoepitopes as biomarkers of cartilage catabolism. *Inflamm Res* 2003;52 (7):277–282. [PubMed: 12892070]
- Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. *Circ Res* 2002;90 (3):251–262. [PubMed: 11861412]
- Gasson JC, Golde DW, Kaufman SE, Westbrook CA, Hewick RM, Kaufman RJ, Wong GG, Temple PA, Leary AC, Brown EL, et al. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. *Nature* 1985;315 (6022):768–771. [PubMed: 3839290]
- Goldberg GI, Wilhelm SM, Kronberger A, Bauer EA, Grant GA, Eisen AZ. Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein. *J Biol Chem* 1986;261 (14):6600–6605. [PubMed: 3009463]
- Gomis-Rüth FX, Gohlke U, Betz M, Knauper V, Murphy G, López-Otin C, Bode W. The helping hand of collagenase-3 (MMP-13): 2.7 Å crystal structure of its C-terminal haemopexin-like domain. *J Mol Biol* 1996;264 (3):556–566. [PubMed: 8969305]
- Gomis-Rüth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov GP, Bartunik H, Bode W. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. *Nature* 1997;389 (6646):77–81. [PubMed: 9288970]
- Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. *Proc Natl Acad Sci USA* 1962;48:1014–1022.
- Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. *J Clin Invest* 1998;102 (11):2002–2010. [PubMed: 9835626]
- Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. *Cancer Cell* 2003;3 (6): 589–601. [PubMed: 12842087]
- Harvey MB, Leco KJ, Arcellana-Panlilio MY, Zhang X, Edwards DR, Schultz GA. Roles of growth factors during peri-implantation development. *Hum Reprod* 1995;10 (3):712–718. [PubMed: 7782459]
- Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. *FEBS Lett* 1992;298 (1):29–32. [PubMed: 1544418]
- Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). *J Cell Sci* 1994;107 (Pt 9):2373–2379. [PubMed: 7844157]
- Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, Takeshita A. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. *Am J Physiol Heart Circ Physiol* 2003;285 (3):H1229–H1235. [PubMed: 12775562]

- Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, Schonbeck U. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. *J Clin Invest* 2001;107 (9):1117–1126. [PubMed: 11342575]
- Heymans S, Lutun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JPM, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JFM, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJAP, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. *Nature Med* 1999;5 (10):1135–1142. [PubMed: 10502816]
- Higashi S, Miyazaki K. Reactive site-modified tissue inhibitor of metalloproteinases-2 inhibits the cell-mediated activation of progelatinase A. *J Biol Chem* 1999;274 (15):10497–10504. [PubMed: 10187841]
- Higashi S, Miyazaki K. Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A. *Biochemistry* 2003;42(21):6514–6526. [PubMed: 12767235]
- Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, Poole AR. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. *J Clin Invest* 1994;93 (4):1722–1732. [PubMed: 7512992]
- Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. *Cell* 1999;99 (1):81–92. [PubMed: 10520996]
- Hou P, Troen T, Ovejero MC, Kirkegaard T, Andersen TL, Byrjalsen I, Ferreras M, Sato T, Shapiro SD, Foged NT, Delaisse JM. Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. *Bone* 2004;34 (1):37–47. [PubMed: 14751561]
- Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. *Nat Rev Drug Discov* 2007;6 (6):480–498. [PubMed: 17541420]
- Huang W, Meng Q, Suzuki K, Nagase H, Brew K. Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases I (TIMP-1) locates an inhibitory region for matrix metalloproteinases. *J Biol Chem* 1997;272 (35):22086–22091. [PubMed: 9268350]
- Hughes S, Agbaje O, Bowen RL, Holliday DL, Shaw JA, Duffy S, Jones JL. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. *Clin Cancer Res* 2007;13 (22 Pt 1):6673–6680. [PubMed: 18006768]
- Huxley-Jones J, Clarke TK, Beck C, Toubaris G, Robertson DL, Boot-Handford RP. The evolution of the vertebrate metzincins; insights from *Ciona intestinalis* and *Danio rerio*. *BMC Evol Biol* 2007;7:63. [PubMed: 17439641]
- Illman SA, Lehti K, Keski-Oja J, Lohi J. Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. *J Cell Sci* 2006;119 (Pt 18):3856–3865. [PubMed: 16940349]
- Inada M, Wang Y, Byrne MH, Rahman MU, Miyaura C, López-Otin C, Krane SM. Critical roles for collagenase-3 (MMP13) in development of growth plate cartilage and in endochondral ossification. *Proc Natl Acad Sci USA* 2004;101 (49):17192–17197. [PubMed: 15563592]
- Itoh Y, Seiki M. MT1-MMP: A potent modifier of pericellular microenvironment. *J Cell Physiol* 2005;206 (1):1–8. [PubMed: 15920734]
- Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N, Aoki T, Seiki M. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. *EMBO J* 2001;20 (17):4782–4793. [PubMed: 11532942]
- Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. *J Immunol* 2002;169 (5):2643–2647. [PubMed: 12193736]
- Itoh Y, Ito N, Nagase H, Evans RD, Bird SA, Seiki M. Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. *Mol Biol Cell* 2006;17 (12):5390–5399. [PubMed: 17050733]
- Iyer S, Visse R, Nagase H, Acharya KR. Crystal Structure of an Active Form of Human MMP-1. *J Mol Biol* 2006;362 (1):78–88. [PubMed: 16890240]



- Jacobsen J, Visse R, Sorensen HP, Enghild JJ, Brew K, Wewer UM, Nagase H. Catalytic properties of ADAM12 and its domain deletion mutants. *Biochemistry* 2008;47 (2):537–547. [PubMed: 18081311]
- Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. *Arterioscler Thromb Vasc Biol* 2004;24(1):54–60. 304. [PubMed: 14551157]
- Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. *Proc Natl Acad Sci USA* 2005;102 (43):15575–15580. [PubMed: 16221765]
- Jozic D, Bourenkov G, Lim NH, Visse R, Nagase H, Bode W, Maskos K. X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding. *J Biol Chem* 2005;280 (10):9578–9585. [PubMed: 15611040]
- Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). *J Biol Chem* 2001;276 (16):12501–12504. [PubMed: 11278243]
- Kennedy AM, Inada M, Krane SM, Christie PT, Harding B, López-Otín C, Sanchez LM, Pannett AA, Dearlove A, Hartley C, Byrne MH, Reed AA, Nesbit MA, Whyte MP, Thakker RV. MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO)). *J Clin Invest* 2005;115 (10):2832–2842. [PubMed: 16167086]
- Kerkelä E, Bohling T, Herva R, Uria JA, Saarialho-Kere U. Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation. *Bone* 2001;29 (5):487–493. [PubMed: 11704502]
- Kerkelä E, Ala-aho R, Klemi P, Grenman S, Shapiro SD, Kähäri VM, Saarialho-Kere U. Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. *J Pathol* 2002;198 (2):258–269. [PubMed: 12237887]
- Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, Brockbank SM, Edwards DR, Parker AE, Clark IM. Expression profiling of metalloproteinases and their inhibitors in cartilage. *Arthritis Rheum* 2004;50 (1):131–141. [PubMed: 14730609]
- Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. *J Clin Invest* 2000;106 (7):857–866. [PubMed: 11018073]
- Kim JW, Simmer JP, Hart TC, Hart PS, Ramaswami MD, Bartlett JD, Hu JC. MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta. *J Med Genet* 2005;42 (3):271–275. [PubMed: 15744043]
- Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. *J Biol Chem* 1993;268 (14):10425–10432. [PubMed: 7683678]
- Knäuper V, Will H, López-Otín C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. *J Biol Chem* 1996;271 (29):17124–17131. [PubMed: 8663255]
- Knäuper V, Docherty AJP, Smith B, Tschesche H, Murphy G. Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis. *FEBS Lett* 1997;405 (1):60–64. [PubMed: 9094424]
- Kubben FJ, Sier CF, Meijer MJ, van den BM, van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. *Br J Cancer* 2006;95 (6):744–751. [PubMed: 16940985]
- Leco KJ, Waterhouse P, Sanchez OH, Gowing KLM, Poole AR, Wakeham A, Mak TW, Khokha R. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). *J Clin Invest* 2001;108 (6):817–829. [PubMed: 11560951]
- Lee MH, Rapti M, Murphy G. Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase. *J Biol Chem* 2003;278 (41):40224–40230. [PubMed: 12869573]

- Lee MH, Rapti M, Knäuper V, Murphy G. Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. *J Biol Chem* 2004a;279 (17):17562–17569. [PubMed: 14734567]
- Lee MH, Rapti M, Murphy G. Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor- $\alpha$ -converting enzyme. *J Biol Chem* 2004b;279 (43):45121–45129. [PubMed: 15308656]
- Lee MH, Rapti M, Murphy G. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor- $\alpha$ -converting enzyme. *J Biol Chem* 2005;280 (16):15967–15975. [PubMed: 15713681]
- Lemaitre V, D'Armiento J. Matrix metalloproteinases in development and disease. *Birth Defects Res C Embryo Today* 2006;78 (1):1–10. [PubMed: 16622845]
- Lepage M, Dow WC, Melchior M, You Y, Fingleton B, Quarles CC, Pepin C, Gore JC, Matrisian LM, McIntyre JO. Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. *Mol Imaging* 2007;6 (6):393–403. [PubMed: 18053410]
- Li J, Brick P, O'Hare MC, Skarzynski T, Lloyd LF, Curry VA, Clark IM, Bigg HF, Hazleman BL, Cawston TE, et al. Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed beta-propeller. *Structure* 1995;3 (6):541–549. [PubMed: 8590015]
- Li W, Gibson CW, Abrams WR, Andrews DW, DenBesten PK. Reduced hydrolysis of amelogenin may result in X-linked amelogenesis imperfecta. *Matrix Biol* 2001;19 (8):755–760. [PubMed: 11223334]
- Libson AM, Gittis AG, Collier IE, Marmer BL, Goldberg GI, Lattman EE. Crystal structure of the haemopexin-like C-terminal domain of gelatinase A [letter]. *Nature Struct Biol* 1995;2 (11):938–942. [PubMed: 7583664]
- Lijnen HR, Soloway P, Collen D. Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. *Circ Res* 1999a;85 (12):1186–1191. [PubMed: 10590246]
- Lijnen HR, van Hoef B, Vanlinthout I, Verstreken M, Rio MC, Collen D. Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. *Arterioscler Thromb Vasc Biol* 1999b;19 (12):2863–2870. [PubMed: 10591662]
- Lohi J, Wilson CL, Roby JD, Parks WC. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. *J Biol Chem* 2001;276 (13):10134–10144. [PubMed: 11121398]
- Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. *J Clin Invest* 2002;110 (5):625–632. [PubMed: 12208863]
- Luo D, Mari B, Stoll I, Anglard P. Alternative splicing and promoter usage generates an intracellular stromelysin 3 isoform directly translated as an active matrix metalloproteinase. *J Biol Chem* 2002;277 (28):25527–25536. [PubMed: 12006591]
- Mahmoodi M, Sahebjam S, Smookler D, Khokha R, Mort JS. Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. *Am J Pathol* 2005;166 (6):1733–1740. [PubMed: 15920158]
- Marchenko ND, Marchenko GN, Weinreb RN, Lindsey JD, Kyshtoobayeva A, Crawford HC, Strongin AY. Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. *Int J Biochem Cell Biol* 2004;36 (5):942–956. [PubMed: 15006646]
- Martignetti JA, Al Aqeel A, Al Sewairi W, Boumah CE, Kambouris M, Al Mayouf S, Sheth KV, Al Eid W, Dowling O, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. *Nature Genet* 2001;28 (3):261–265. [PubMed: 11431697]
- Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. *Cancer Metastasis Rev* 2007;26 (3–4):717–724. [PubMed: 17717634]
- Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. *Biochimie* 2005;87 (3–4):249–263. [PubMed: 15781312]

- Masson R, Lefebvre O, Noel A, El Fahime M, Chenard MP, Wendling C, Kebers F, LeMeur M, Dierich A, Foidart JM, Basset P, Rio MC. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. *J Cell Biol* 1998;140 (6):1535–1541. [PubMed: 9508784]
- Matrisian LM, Glaichenhaus N, Gesnel MC, Breathnach R. Epidermal growth factor and oncogenes induce transcription of the same cellular mRNA in rat fibroblasts. *EMBO J* 1985;4 (6):1435–1440. [PubMed: 3875482]
- Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. *J Clin Invest* 2005a;115 (3):599–609. [PubMed: 15711638]
- Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. *J Clin Invest* 2005b;115 (3):599–609. [PubMed: 15711638]
- Meng Q, Malinovskii V, Huang W, Hu YJ, Chung L, Nagase H, Bode W, Maskos K, Brew K. Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate. *J Biol Chem* 1999;274 (15):10184–10189. [PubMed: 10187802]
- Milner JM, Cawston TE. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. *Curr Drug Targets Inflamm Allergy* 2005;4 (3):363–375. [PubMed: 16101546]
- Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, Foekens JA, van de Vijver MJ, Massague J. Lung metastasis genes couple breast tumor size and metastatic spread. *Proc Natl Acad Sci USA* 2007;104 (16):6740–6745. [PubMed: 17420468]
- Mix KS, Sporn MB, Brinckerhoff CE, Eyre D, Schurman DJ. Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis. *Clin Orthop Relat Res* 2004;(427 Suppl):S129–S137. [PubMed: 15480055]
- Momohara S, Okamoto H, Komiya K, Ikari K, Takeuchi M, Tomatsu T, Kamatani N. Matrix metalloproteinase 28/epilysin expression in cartilage from patients with rheumatoid arthritis and osteoarthritis: comment on the article by Kevorkian et al. *Arthritis Rheum* 2004;50 (12):4074–4075. [PubMed: 15593191]
- Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, Schneider G, Tryggvason K. Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed. *Science* 1999;284 (5420):1667–1670. [PubMed: 10356396]
- Morgunova E, Tuuttila A, Bergmann U, Tryggvason K. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. *Proc Natl Acad Sci USA* 2002;99 (11):7414–7419. [PubMed: 12032297]
- Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, Abe E, Diouri J, Aqeel AA, Wylie JD, Oblander SA, Madri J, Bianco P, Apte SS, Zaidi M, Doty SB, Majeska RJ, Schaffler MB, Martignetti JA. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. *Hum Mol Genet* 2007;16 (9):1113–1123. [PubMed: 17400654]
- Mott JD, Thomas CL, Rosenbach MT, Takahara K, Greenspan DS, Banda MJ. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. *J Biol Chem* 2000;275 (2):1384–1390. [PubMed: 10625689]
- Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? *Nat Clin Pract Rheumatol* 2008;4 (3):128–135. [PubMed: 18253109]
- Murphy G, McAlpine CG, Poll CT, Reynolds JJ. Purification and characterization of a bone metalloproteinase that degrades gelatin and types IV and V collagen. *Biochim Biophys Acta* 1985;831 (1):49–58. [PubMed: 2994741]
- Murphy G, Houbrechts A, Cockett MI, Williamson RA, O'Shea M, Docherty AJP. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity [published erratum appears in *Biochemistry* 1991 Oct 22;30(42):10362]. *Biochemistry* 1991;30 (33):8097–8102. [PubMed: 1868085]

- Murphy G, Segain JP, O'Shea M, Cockett M, Ioannou C, Lefebvre O, Chambon P, Basset P. The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. *J Biol Chem* 1993;268 (21):15435–15441. [PubMed: 8340372]
- Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, Willenbrock F, Docherty AJP. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. *J Biol Chem* 1994;269 (9):6632–6636. [PubMed: 8120015]
- Murphy G, Knäuper V, Atkinson S, Butler G, English W, Hutton M, Stracke J, Clark I. Matrix metalloproteinases in arthritic disease. *Arthritis Res* 2002;4 (Suppl 3):S39–S49. [PubMed: 12110122]
- Nagase, H. Substrate specificity of MMPs. In: Clendeninn, NJ.; Appelt, K., editors. *Matrix Metalloproteinase Inhibitors in Cancer Therapy*. Humana Press; Totowa, New Jersey: 2001. p. 39-66.
- Nagase H, Suzuki K, Cawston TE, Brew K. Involvement of a region near valine-69 of tissue inhibitor of metalloproteinases (TIMP)-1 in the interaction with matrix metalloproteinase 3 (stromelysin 1). *Biochem J* 1997;325 (Part1):163–167. [PubMed: 9224642]
- Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc Res* 2006;69 (3):562–573. [PubMed: 16405877]
- Nakamura M, Ishida E, Shimada K, Kishi M, Nakase H, Sakaki T, Konishi N. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. *Lab Invest* 2005;85 (2):165–175. [PubMed: 15592495]
- Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. *Physiol Rev* 2005;85 (1):1–31. [PubMed: 15618476]
- Newby AC, Johnson JL. Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability. *Circ Res* 2005;97 (10):958–960. [PubMed: 16284186]
- Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor–host interface. *Semin Cell Dev Biol* 2008;19 (1):52–60. [PubMed: 17625931]
- Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, Ide C, Horan TP, Arakawa T, Yoshida H, Nishikawa SI, Itoh Y, Seiki M, Itohara S, Takahashi C, Noda M. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. *Cell* 2001;107 (6):789–800. [PubMed: 11747814]
- Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. *J Biol Chem* 1997;272 (4): 2446–2451. [PubMed: 8999957]
- Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. *Mol Biotechnol* 2002;22 (1):51–86. [PubMed: 12353914]
- Overall CM, Blobel CP. In search of partners: linking extracellular proteases to substrates. *Nat Rev Mol Cell Biol* 2007;8 (3):245–257. [PubMed: 17299501]
- Overall CM, Lopez-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. *Nat Rev Cancer* 2002;2 (9):657–672. [PubMed: 12209155]
- Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. *Nat Rev Mol Cell Biol* 2007;8 (3):221–233. [PubMed: 17318226]
- Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. *Nat Rev Immunol* 2004;4 (8):617–629. [PubMed: 15286728]
- Patterson ML, Atkinson SJ, Knäuper V, Murphy G. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. *FEBS Lett* 2001;503 (2–3):158–162. [PubMed: 11513874]
- Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. *Nature* 1995;375 (6528):244–247. [PubMed: 7746327]
- Pei DQ, Kang TB, Qi HX. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. *J Biol Chem* 2000;275 (43):33988–33997. [PubMed: 10945999]
- Pendas AM, Knäuper V, Puente XS, Llano E, Mattei MG, Apte S, Murphy G, López-Otín C. Identification and characterization of a novel human matrix metalloproteinase with unique structural


- characteristics, chromosomal location, and tissue distribution. *J Biol Chem* 1997;272 (7):4281–4286. [PubMed: 9020145]
- Pendas AM, Folgueras AR, Llano E, Caterina J, Frerard F, Rodriguez F, Astudillo A, Noel A, Birkedal-Hansen H, Lopez-Otin C. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. *Mol Cell Biol* 2004;24 (12):5304–5313. [PubMed: 15169894]
- Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. *Nat Med* 2003;9 (4):407–415. [PubMed: 12652295]
- Ravanti L, Kähäri VM. Matrix metalloproteinases in wound repair. *Int J Mol Med* 2000;6 (4):391–407. [PubMed: 10998429]
- Rodriguez-Manzanique JC, Westling J, Thai SN, Luque A, Knäuper V, Murphy G, Sandy JD, Iruela-Arispe ML. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. *Biochem Biophys Res Commun* 2002;293 (1):501–508. [PubMed: 12054629]
- Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, Grau E, Mao J, Sathe GM, Ohlstein EH, Yue TL. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. *Cardiovasc Res* 2002a;54 (3):549–558. [PubMed: 12031700]
- Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, Grau E, Mao J, Sathe GM, Ohlstein EH, Yue TL. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. *Cardiovasc Res* 2002b;54 (3):549–558. [PubMed: 12031700]
- Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, Grau E, Mao J, Sathe GM, Ohlstein EH, Yue TL. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. *Cardiovasc Res* 2002c;54 (3):549–558. [PubMed: 12031700]
- Rosenblum G, Van den Steen PE, Cohen SR, Grossmann JG, Frenkel J, Sertchook R, Slack N, Strange RW, Opendakker G, Sagi I. Insights into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B. *Structure* 2007;15(10):1227–1236. [PubMed: 17937912]
- Ryu OH, Fincham AG, Hu CC, Zhang C, Qian Q, Bartlett JD, Simmer JP. Characterization of recombinant pig enamelysin activity and cleavage of recombinant pig and mouse amelogenins. *J Dent Res* 1999;78 (3):743–750. [PubMed: 10096449]
- Saarialho-Kere U, Kerkela E, Jahkola T, Suomela S, Keski-Oja J, Lohi J. Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. *J Invest Dermatol* 2002;119 (1):14–21. [PubMed: 12164918]
- Sadowski T, Dietrich S, Muller M, Havlickova B, Schunck M, Proksch E, Muller MS, Sedlacek R. Matrix metalloproteinase-19 expression in normal and diseased skin: dysregulation by epidermal proliferation. *J Invest Dermatol* 2003;121 (5):989–996. [PubMed: 14708597]
- Sadowski T, Dietrich S, Koschinsky F, Ludwig A, Proksch E, Titz B, Sedlacek R. Matrix metalloproteinase 19 processes the laminin 5 gamma 2 chain and induces epithelial cell migration. *Cell Mol Life Sci* 2005;62 (7–8):870–880. [PubMed: 15868410]
- Shi YB, Li Q, Damjanovski S, Amano T, Ishizuya-Oka A. Regulation of apoptosis during development – input from the extracellular matrix. *Int J Mol Med* 1998;2 (3):273–282. [PubMed: 9855698]
- Shiple J, Doyle GA, Fliszar CJ, Ye QZ, Johnson LL, Shapiro SD, Welgus HG, Senior RM. The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. *J Biol Chem* 1996a;271 (8):4335–4341. [PubMed: 8626782]
- Shiple J, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. *Proc Natl Acad Sci USA* 1996b;93 (9):3942–3946. [PubMed: 8632994]
- Skoog T, Ahokas K, Orsmark C, Jeskanen L, Isaka K, Saarialho-Kere U. MMP-21 is expressed by macrophages and fibroblasts in vivo and in culture. *Exp Dermatol* 2006;15 (10):775–783. [PubMed: 16984259]
- Smeets TJ, Kraan MC, Galjaard S, Youssef PP, Smith MD, Tak PP. Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA. *Ann Rheum Dis* 2001;60 (6):561–565. [PubMed: 11350843]




- Smith MR, Kung HF, Durum SK, Colburn NH, Sun Y. TIMP-3 induces cell death by stabilizing TNF- $\alpha$  receptors on the surface of human colon carcinoma cells. *Cytokine* 1997;9 (10):770–780. [PubMed: 9344510]
- Soloway PD, Alexander CM, Werb Z, Jaenisch R. Targeted mutagenesis of *Timp-1* reveals that lung tumor invasion is influenced by *Timp-1* genotype of the tumor but not by that of the host. *Oncogene* 1996;13 (11):2307–2314. [PubMed: 8957071]
- Sternlicht MD, Lochter A, Sympon CJ, Huey B, Rougler JP, Gray JW, Pinkel D, Bissell MJ, Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. *Cell* 1999;98 (2): 137–146. [PubMed: 10428026]
- Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. *Annu Rev Cell Dev Biol* 2001:17463–17516.
- Stetler-Stevenson WG, Bersch N, Golde DW. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. *FEBS Lett* 1992;296 (2):231–234. [PubMed: 1370805]
- Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, Fosang AJ, Schorpp-Kistner M, Angel P, Werb Z. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. *Development* 2004;131 (23):5883–5895. [PubMed: 15539485]
- Stracke JO, Hutton M, Stewart M, Pendas AM, Smith B, Lopez-Otin C, Murphy G, Knauper V. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19 – Evidence for a role as a potent basement membrane degrading enzyme. *J Biol Chem* 2000;275 (20): 14809–14816. [PubMed: 10809722]
- Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. *J Biol Chem* 1990;265 (29):17401–17404. [PubMed: 1698775]
- Suenaga N, Mori H, Itoh Y, Seiki M. CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. *Oncogene* 2005;24 (5):859–868. [PubMed: 15558018]
- Szabova L, Chrysovergis K, Yamada SS, Holmbeck K. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. *Oncogene*. 2007
- Tsukada H, Pourmotabbed T. Unexpected crucial role of residue 272 in substrate specificity of fibroblast collagenase. *J Biol Chem* 2002;277 (30):27378–27384. [PubMed: 12011042]
- Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. *Int J Cancer* 1998;75 (2):246–253. [PubMed: 9462715]
- Van den Steen PE, Van Aelst I, Hvidberg V, Piccard H, Fiten P, Jacobsen C, Moestrup SK, Fry S, Royle L, Wormald MR, Wallis R, Rudd PM, Dwek RA, Opdenakker G. The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. *J Biol Chem* 2006;281 (27):18626–18637. [PubMed: 16672230]
- Van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, Verheijen JH, Breedveld FC, Gay RE, Gay S, Huizinga TW, Pap T. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. *Gene Ther* 2003;10 (3):234–242. [PubMed: 12571631]
- Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. *Proc Natl Acad Sci USA* 1990;87 (14):5578–5582. [PubMed: 2164689]
- Vater CA, Mainardi CL, Harris ED Jr. Inhibitor of human collagenase from cultures of human tendon. *J Biol Chem* 1979;254 (8):3045–3053. [PubMed: 218961]
- Velasco G, Pendas AM, Fueyo A, Knäuper V, Murphy G, López-Otín C. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. *J Biol Chem* 1999;274 (8):4570–4576. [PubMed: 9988691]
- Voils SA, Evans ME, Lane MT, Schosser RH, Rapp RP. Use of macrolides and tetracyclines for chronic inflammatory diseases. *Ann Pharmacother* 2005;39 (1):86–94. [PubMed: 15562139]

- Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology [Review]. *Genes Dev* 2000;14 (17):2123–2133. [PubMed: 10970876]
- Wang WM, Ge G, Lim NH, Nagase H, Greenspan DS. TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. *Biochem J* 2006;398 (3):515–519. [PubMed: 16771712]
- Wei S, Chen Y, Chung L, Nagase H, Brew K. Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors. *J Biol Chem* 2003;278 (11):9831–9834. [PubMed: 12515831]
- Wei S, Kashiwagi M, Kota S, Xie Z, Nagase H, Brew K. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor- $\alpha$ -converting enzyme. *J Biol Chem* 2005;280 (38):32877–32882. [PubMed: 16079149]
- Weissleder R. Molecular imaging in cancer. *Science* 2006;312 (5777):1168–1171. [PubMed: 16728630]
- Welgus HG, Stricklin GP, Eisen AZ, Bauer EA, Cooney RV, Jeffrey JJ. A specific inhibitor of vertebrate collagenase produced by human skin fibroblasts. *J Biol Chem* 1979;254 (6):1938–1943. [PubMed: 217874]
- Welgus HG, Jeffrey JJ, Eisen AZ, Roswit WT, Stricklin GP. Human skin fibroblast collagenase: interaction with substrate and inhibitor. *Coll Relat Res* 1985;5 (2):167–179. [PubMed: 2988853]
- Williamson RA, Hutton M, Vogt G, Rapti M, Knäuper V, Carr MD, Murphy G. Tyrosine 36 plays a critical role in the interaction of the AB loop of tissue inhibitor of metalloproteinases-2 with matrix metalloproteinase-14. *J Biol Chem* 2001;276 (35):32966–32970. [PubMed: 11390386]
- Williamson RA, Marston FAO, Angal S, Koklitis P, Panico M, Morris HR, Carne AF, Smith BJ, Harris TJR, Freedman RB. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). *Biochem J* 1990;268 (2):267–274. [PubMed: 2163605]
- Williamson RA, Martorell G, Carr MD, Murphy G, Docherty AJP, Freedman RB, Feeney J. Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family. *Biochemistry* 1994;33 (39):11745–11759. [PubMed: 7918391]
- Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. *Proc Natl Acad Sci USA* 1997;94 (4):1402–1407. [PubMed: 9037065]
- Wingfield PT, Sax JK, Stahl SJ, Kaufman J, Palmer I, Chung V, Corcoran ML, Kleiner DE, Stetler-Stevenson WG. Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in *Escherichia coli* – Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. *J Biol Chem* 1999;274 (30):21362–21368. [PubMed: 10409697]
- Woolley DE, Glanville RW, Crossley MJ, Evanson JM. Purification of rheumatoid synovial collagenase and its action on soluble and insoluble collagen. *Eur J Biochem* 1975;54 (2):611–622. [PubMed: 170094]
- Wright RW, Allen T, El Zawawy HB, Brodt MD, Silva MJ, Gill CS, Sandell LJ. Medial collateral ligament healing in macrophage metalloelastase (MMP-12)-deficient mice. *J Orthop Res* 2006;24 (11):2106–2113. [PubMed: 16947777]
- Wu W, Billingham RC, Pidoux I, Antoniou J, Zukor D, Tanzer M, Poole AR. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. *Arthritis Rheum* 2002;46 (8):2087–2094. [PubMed: 12209513]
- Wu YI, Munshi HG, Sen R, Snipas SJ, Salvesen GS, Fridman R, Stack MS. Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. *J Biol Chem* 2004;279 (9):8278–8289. [PubMed: 14670950]
- Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. *J Cell Physiol* 2007;211 (1):19–26. [PubMed: 17167774]
- Yang MZ, Kurkinen M. Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts – CMMP, Xenopus XMMP, and human MMP-19 have a conserved unique cysteine in the catalytic domain. *J Biol Chem* 1998;273 (28):17893–17900. [PubMed: 9651395]

- Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. *Matrix Biol* 2000;19 (7):623–629. [PubMed: 11102751]
- Ye S, Patodi N, Walker-Bone K, Reading I, Cooper C, Dennison E. Variation in the matrix metalloproteinase-3, -7, -12 and -13 genes is associated with functional status in rheumatoid arthritis. *Int J Immunogenet* 2007;34 (2):81–85. [PubMed: 17373931]




**Fig. 1.** Domain structures of the matrixin family. See Table 1 for the domain arrangement of each MMP. ss, signal sequence; pro, pro-domain, FNII, fibronectin type II motif; L1, linker 1; L2, linker 2; Mb, plasma membrane; TM, transmembrane domain; CT, cytoplamic tail; CysR, cysteine rich; Ig, immunoglobulin domain; GPI, glycosylphosphatidylinositol anchor; C, cysteine.




**Fig. 2.** The three-dimensional diagram of human proMMP-2 and TIMP-2 complex. The pro-domain is shown in green, catalytic domain in red, fibronectin type II domains in blue, hemopexin domain in orange, and TIMP-2 in pink. Zinc ion is in green sphere, calcium ion in blue sphere and disulfide bonds in yellow. The image was prepared by Rob Visse of Imperial College London based on Brookhaven Protein Data Bank entry 1GXD.<sup>11</sup>





**Fig. 3.** The three-dimensional diagram of TIMP-1 bound to the catalytic domain of MMP-3. (A) TIMP-1-MMP-3 complex. (B) The reactive centre residues of TIMP-1 in the active site of MMP-3. TIMP-1 is in red, MMP-3 is in blue. Disulfide bonds are shown in yellow, zinc ions in pink and calcium ions in blue. The image was prepared by Rob Visse of Imperial College London based on Brookhaven Protein Data Bank entry 1UEA.



**Fig. 4.** Superimposition of the N-terminal domains of TIMP-1 and TIMP-2. TIMP-1 is shown in blue and TIMP-2 in orange. The residues subjected to mutagenesis studies are illustrated and disulfide bonds are in yellow. The image was prepared by Rob Visse of Imperial College London based on Brookhaven Protein Data Bank entries 1UEA for TIMP-1 and IBQQ for TIMP-2.

Table 1

Human matrixins and their domain composition

Enzyme	MMP	Chromosomal location (human)	Domain composition												
			SS	Pro	CS	RX[R/K]R	Cat	FN2	Lk1	Hpx	Lk2	TM	GPI	Cyt	CysR-Ig
Collagenases															
Interstitial collagenase;	MMP-1	11q22-q23	+	+	+	-	+	-	+	+	+				
Collagenase 1															
Neutrophil collagenase;	MMP-8	11q21-q22	+	+	+	-	+	-	+	+	+				
Collagenase 2															
Collagenase 3	MMP-13	11q22.3	+	+	+	-	+	-	+	+	+				
Gelatinases															
Gelatinase A	MMP-2	16q13	+	+	+	-	+	+	+	+	+				
Gelatinase B	MMP-9	20q11.2-q13.1	+	+	+	-	+	+	+	+	+				
Stromelysins															
Stromelysin 1	MMP-3	11q23	+	+	+	-	+	-	+	+	+				
Stromelysin 2	MMP-10	11q22.3-q23	+	+	+	-	+	-	+	+	+				
Matrilysins															
Matrilysin 1	MMP-7	11q21-q22	+	+	+	-	+	-	+	-	-				
Matrilysin 2	MMP-26	11p15	+	+	+	-	+	-	+	-	-				
Stromelysin 3	MMP-11	22q11.2	(+)	(+)	+	+	+	-	+	+	+				
Membrane-type MMPs															
(A) Transmembrane-type															
MT1-MMP	MMP-14	14q11-q12	+	+	+	+	+	-	+	+	+				
MT2-MMP	MMP-15	15q13-q21	+	+	+	+	+	-	+	+	+				
MT3-MMP	MMP-16	8q21	+	+	+	+	+	-	+	+	+				
MT5-MMP	MMP-24	20q11.2	+	+	+	+	+	-	+	+	+				
(B) GPI-anchored															
MT4-MMP	MMP-17	12q24.3	+	+	+	+	+	-	+	+	+				
MT6-MMP	MMP-25	16p13.3	+	+	+	+	+	-	+	+	+				
Others															
Macrophage elastase	MMP-12	11q22.2-q22.3	+	+	+	-	+	-	+	+	+				

Enzyme	MMP	Chromosomal location (human)	Domain composition														
			SS	Pro	CS	RX R K R	Cat	FN2	Lk 1	Hpx	Lk 2	TM	GPI	Cyt	CysR-Ig		
-	MMP-19	12q14	+	+	+	-	+	-	+	+	+	+	+	+	+	+	+
Enamelysin	MMP-20	11q22.3	+	+	+	-	+	-	+	+	+	+	+	+	+	+	+
-	MMP-21	10	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+
CA-MMP	MMP-23	1p36.3	+	+	-	+	+	-	+	-	-	-	-	-	-	-	+
-	MMP-27	11q24	+	+	+	-	+	-	+	+	+	+	+	+	+	+	+
Epilysin	MMP-28	17q21.1	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+

Human matrixins are grouped based on trivial names. SS, signal peptide; Pro, pro-domain; CS, cysteine switch motif; RX|R|K|R, proprotein convertase recognition sequence; FN2, fibronectin type II motif; LK, linker; TM, transmembrane domain; GPI, glycosylphosphatidylinositol anchoring sequence; Cyt, cytoplasmic domain; CysR-Ig, cysteine rich and Ig domain; ( ) indicates a splice variant lacking SS and Pro.

**Table 2***Mmp* and *Timp* gene ablation in mice: specific disease phenotypes

Gene	<i>In vivo</i> phenotype	Reference
<b>Cancer</b>		
<i>Mmp2</i>	Reduced pancreatic tumorigenesis	Bergers et al. (2000)
<i>Mmp7</i>	Reduced intestinal adenoma formation	Wilson et al. (1997)
<i>Mmp8</i>	Papillomas increased size (males)	Balbin et al. (2003)
<i>Mmp9</i>	Reduced pancreatic tumorigenesis	Bergers et al. (2000)
<i>Mmp11</i>	Delayed mammary tumorigenesis	Masson et al. (1998)
<i>Mmp14</i>	Accelerated mammary tumorigenesis, reduced metastases	Szabova et al. (2007)
<i>Mmp9</i>	Less skin fibrosarcomas, longer latency	Pendas et al. (2004)
<i>Timp1</i>	Suppression or potentiation of lung tumor metastases	Soloway et al. (1996)
	Increased tumor cell sensitivity to chemotherapy	Davidson et al. (2006)
<i>Timp3</i>	Enhanced metastatic dissemination of melanoma and lymphoma	Cruz-Munoz et al. (2006)
<b>Vascular diseases</b>		
<i>Mmp2</i>	Reduction neointima formation on vascular injury Protection from cardiac rupture post-myocardial infarction	Johnson and Galis (2004) and Matsumura et al. (2005b)
<i>Mmp9</i>	Reduction neointima formation on vascular injury Protection from cardiac rupture post-myocardial infarction	Johnson and Galis (2004) Ducharme et al. (2000)
<i>Mmp11</i>	Accelerated neointima formation on vascular injury	Lijnen et al. (1999b)
<i>Timp1</i>	Accelerated neointima formation on vascular injury Spontaneous cardiac dilatation, augmented dysfunction post-myocardial infarction	Lijnen et al. (1999a) Creemers et al. (2003)
<i>Timp3</i>	Spontaneous dilated cardiomyopathy	Fedak et al. (2004)
<b>Arthritis</b>		
		Reference
<i>Mmp2</i>	Increased immune-complex mediated arthritis	Itoh et al. (2002)
<i>Mmp9</i>	Decreased immune-complex mediated arthritis	Itoh et al. (2002)
<i>Mmp12</i>	Reduced macrophage numbers in ligament injury	Wright et al. (2006)
<i>Mmp13</i>	Spontaneous abnormal growth plate, increased trabecular bone	Stickens et al. (2004)
<i>Mmp14</i>	Defects in skeletal development, arthritis and connective tissue disease	Holmbeck et al. (1999)
<i>Timp3</i>	Enhanced inflammatory response in antigen induced arthritis	Mahmoodi et al. (2005)

Ablation of individual *Mmp* or *Timp* genes in mice has been used to study the change in phenotype of established disease models. Some representative examples of the major changes seen in cancer, vascular diseases and arthritis models are cited.